What does this research mean for the field?

Combined anti-PD-1 and EGFR neoadjuvant immunotherapy in head and neck squamous cell carcinoma is associated with an increased risk of postoperative pulmonary embolism and cardiovascular accidents, necessitating multidisciplinary team management. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

March 3, 2026Open Access

Management of head and neck squamous cell carcinoma combined by pulmonary embolism: An adverse event of combined anti–PD-1 and EGFR neoadjuvant immunotherapy

Key Points

Postoperative pulmonary embolism is linked to higher cardiovascular risks among patients.
The combination of anti–PD-1 and EGFR therapies significantly influences postoperative health outcomes.

Structured PICO

Population

Patients with head and neck squamous cell carcinoma experiencing postoperative pulmonary embolism following combined anti-PD-1 and EGFR neoadjuvant immunotherapy

Intervention

Multidisciplinary team (MDT) management

Multidisciplinary team management is crucial for handling severe postoperative complications like pulmonary embolism exacerbated by anti-PD-1 and EGFR neoadjuvant therapy in head and neck squamous cell carcinoma.

Abstract

• The occurrence of postoperative combined pulmonary embolism is associated with increased risk of cardiovascular accidents due to neoadjuvant therapy. • MDT is a fundamental safeguard in the face of severe postoperative complications exacerbated by aPD-1 and aEGFR-based neoadjuvant therapy.

Read Full Paperexternally

Bookmark

View Full Paper

Cite This Study

Zhi et al. (Thu,) studied this question.

synapsesocial.com/papers/69a75ddbc6e9836116a28229 https://doi.org/https://doi.org/10.1016/j.asjsur.2025.12.281

Bookmark

View Full Paper